IONS Q2 2018 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$118M+4.9% YoY

Gross Profit

$118M100.0% margin

Operating Income

-$50M-42.7% margin

Net Income

-$40M-34.3% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

-18.5%

Cash Flow

Operating Cash Flow

$500M

Free Cash Flow

$492M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.4B

Stockholders' Equity

$696M

Cash & Equivalents

$805M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118M	$112M	+4.9%
Gross Profit	$118M	$29M	+309.3%
Operating Income	-$50M	$6M	-879.6%
Net Income	-$40M	-$3M	-1208.1%

Revenue Segments

Research and Development Revenue Under Collaborative Agreements

$61M35%

Commercial

$57M33%

SPINRAZA Royalties

$57M32%

Licensing and Other Royalties

$545,0000%